ReviewEye (London, England)2023
Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes.
Review in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 42 citations in OpenAlex.
- Comparative study on the efficacy of Conbercept and Aflibercept in the treatment of neovascular age-related macular degeneration.Scientific reports · 2024Trial
- Early Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in France: A Retrospective Study.Ophthalmology and therapy · 2026Article
- Insights into the modulation of age-related macular degeneration: Molecular and systems-level perspectives.Acta ophthalmologica · 2026Article
- Eighteen-month real-world outcomes of intravitreal aflibercept 8 mg in treatment-naïve neovascular age-related macular degeneration: a UK single-centre experience.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Association between choroidal structure and retinal fluid location in type 1 neovascular age-related macular degeneration.Eye (London, England) · 2026Article
- Early Structure-Function Correlates in Neovascular Age-Related Macular Degeneration Using Artificial Intelligence-Derived OCT Biomarkers.Ophthalmology science · 2026Article
- From Subretinal to Intraretinal Fluid in Type 1 Macular Neovascularization: A Clinicopathologic Disease Transition Model.Investigative ophthalmology & visual science · 2026Article
- Machine Learning to Predict Outcomes of Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration.Ophthalmology science · 2026Article
- Real-world outcomes of faricimab in treatment-naïve patients with neovascular age-related macular degeneration.BMC ophthalmology · 2026Article
- α-Crystallins and vascular endothelial growth factor in aqueous humor of patients with neovascular age-related macular degeneration.Japanese journal of ophthalmology · 2026Article
- Article
- Continuity of care and risk of vision loss in patients with newly developed macular degeneration.Acta ophthalmologica · 2026Article
- Early prediction of macular neovascularization phenotypes and prognostic evolution.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Observational
- Aflibercept 8 mg in Neovascular AMD-A Fast-Drying Anti-VEGF Drug: A Prospective Morpho-Functional Pilot Study.Ophthalmology and therapy · 2026Article
- Intravitreal anti-VEGF therapy for extrafoveal macular neovascularisation secondary to age-related macular degeneration: five-year results in a tertiary centre.Eye (London, England) · 2026Article
- CRX is an intrinsic suppressor of epithelial‒mesenchymal transition in retinal pigment epithelial cells: a promising therapeutic avenue for subretinal fibrosis.Cell death & disease · 2025Article
- Luteolin alleviates angiogenesis in HUVECs by inhibiting VEGFA expression: integrating network pharmacology and experimental validation.Scientific reports · 2025Article
- A Pilot Study on Structural Changes of Choroidal Vasculature Following Intravitreal Anti-VEGF Injection in Neovascular Age-Related Macular Degeneration: Faricimab vs Ranibizumab.Journal of clinical medicine · 2025Article
- 6-month outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration and their relationships with clinical findings: a multicentre cohort study from the J-CREST.BMJ open ophthalmology · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 9 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this review is to identify the common characteristics and prognoses of different subtypes of neovascular age-related macular degeneration (nAMD). We also propose recommendations on how to tailor treatments to the subtype of neovessels to optimise patient outcomes. The authors, selected members of the Vision Academy, met to discuss treatment outcomes in nAMD according to macular neovascularisation (MNV) subtypes, using evidence from a literature search conducted on the PubMed database (cut-off date: March 2019). This review article summarises the recommendations of the Vision Academy on how the characterisation of MNV subtypes can optimise treatment outcomes in nAMD. The identification of MNV subtypes has been facilitated by the advent of multimodal imaging. Findings from fluorescein angiography, indocyanine green angiography and spectral-domain optical coherence tomography collectively help refine and standardise the determination of the MNV subtype. To date, three subtypes have been described in the literature and have specific characteristics, as identified by imaging. Type 1 MNV is associated with better long-term outcomes but usually requires more intense anti-vascular endothelial growth factor dosing. Type 2 MNV typically responds quickly to treatment but is more prone to the development of fibrotic scars, which may be associated with poorer outcomes. Type 3 MNV tends to be highly sensitive to anti-vascular endothelial growth factor treatment but may be associated with a higher incidence of outer retinal atrophy, compared with other subtypes. Accurately assessing the MNV subtype provides information on prognosis and helps to optimise the management of patients with nAMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.